262 related articles for article (PubMed ID: 28669130)
1. Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation.
van der Zwan M; Baan CC; van Gelder T; Hesselink DA
Clin Pharmacokinet; 2018 Feb; 57(2):191-207. PubMed ID: 28669130
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.
Morgan RD; O'Callaghan JM; Knight SR; Morris PJ
Transplantation; 2012 Jun; 93(12):1179-88. PubMed ID: 22660659
[TBL] [Abstract][Full Text] [Related]
3. Induction therapy in renal transplant recipients: how convincing is the current evidence?
Wagner SJ; Brennan DC
Drugs; 2012 Mar; 72(5):671-83. PubMed ID: 22439670
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results.
Kaufman DB; Leventhal JR; Axelrod D; Gallon LG; Parker MA; Stuart FP
Am J Transplant; 2005 Oct; 5(10):2539-48. PubMed ID: 16162205
[TBL] [Abstract][Full Text] [Related]
6. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
7. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin.
Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Doares W; Kaczmorski S; Farney AC
Expert Opin Biol Ther; 2014 Dec; 14(12):1723-30. PubMed ID: 25156622
[TBL] [Abstract][Full Text] [Related]
8. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
; Haynes R; Harden P; Judge P; Blackwell L; Emberson J; Landray MJ; Baigent C; Friend PJ
Lancet; 2014 Nov; 384(9955):1684-90. PubMed ID: 25078310
[TBL] [Abstract][Full Text] [Related]
10. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.
Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC
Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073
[TBL] [Abstract][Full Text] [Related]
11. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.
Deeks ED; Keating GM
Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
Farney A; Sundberg A; Moore P; Hartmann E; Rogers J; Doares W; Jarrett A; Adams P; Stratta R
Clin Transplant; 2008; 22(1):41-9. PubMed ID: 18217904
[TBL] [Abstract][Full Text] [Related]
13. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.
Ruggenenti P; Codreanu I; Cravedi P; Perna A; Gotti E; Remuzzi G
Clin J Am Soc Nephrol; 2006 May; 1(3):546-54. PubMed ID: 17699258
[TBL] [Abstract][Full Text] [Related]
14. Does Induction Type Influence Outcomes in Kidney Transplant Recipients at Different Phases of Hepatitis B Infection?
Sureshkumar KK; Chopra B
Exp Clin Transplant; 2019 Aug; 17(4):457-460. PubMed ID: 30066624
[TBL] [Abstract][Full Text] [Related]
15. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
Saull HE; Enderby CY; Gonwa TA; Wadei HM
Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
[TBL] [Abstract][Full Text] [Related]
16. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
17. Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation.
Koyawala N; Silber JH; Rosenbaum PR; Wang W; Hill AS; Reiter JG; Niknam BA; Even-Shoshan O; Bloom RD; Sawinski D; Nazarian S; Trofe-Clark J; Lim MA; Schold JD; Reese PP
J Am Soc Nephrol; 2017 Jul; 28(7):2188-2200. PubMed ID: 28320767
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
[TBL] [Abstract][Full Text] [Related]
19. Basiliximab is associated with a lower incidence of De novo donor-specific HLA antibodies in kidney transplant recipients: A single-center experience.
Jarmi T; Abdelmoneim Y; Li Z; Jebrini A; Elrefaei M
Transpl Immunol; 2023 Apr; 77():101778. PubMed ID: 36584928
[TBL] [Abstract][Full Text] [Related]
20. Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients.
Guthoff M; Berger K; Althaus K; Mühlbacher T; Bakchoul T; Steurer W; Nadalin S; Königsrainer A; Heyne N
BMC Nephrol; 2020 May; 21(1):178. PubMed ID: 32404066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
